Edition:
United Kingdom

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

18.86USD
23 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$18.86
Open
$19.01
Day's High
$19.18
Day's Low
$18.70
Volume
196,926
Avg. Vol
349,450
52-wk High
$21.47
52-wk Low
$11.43

Latest Key Developments (Source: Significant Developments)

Halozyme Reports Q4 Earnings Per Share $0.85
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME REPORTS FOURTH QUARTER AND FULL-YEAR 2017 RESULTS.Q4 EARNINGS PER SHARE $0.85.Q4 REVENUE $189.6 MILLION VERSUS $39 MILLION.REITERATED 2018 FINANCIAL GUIDANCE FOR NET REVENUE OF $115 MILLION TO $125 MILLION.  Full Article

Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018.HALOZYME THERAPEUTICS INC - ‍ FORECASTS POTENTIAL ROYALTY REVENUE FOR ENHANZE TO REACH NEARLY $1 BILLION IN 2027 ​.HALOZYME THERAPEUTICS INC - ‍EXPECTS ADDITIONAL PARTNERS TO BEGIN THREE PHASE 1 STUDIES WITH NEW TARGETS FOR ENHANZE​ IN 2018.  Full Article

Halozyme reports Q3 EPS of $0.02
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Halozyme Therapeutics Inc :Halozyme reports third quarter 2017 results.Q3 earnings per share $0.02.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Q3 revenue $63.7 million versus i/b/e/s view $59 million.Sees FY 2017 ‍net revenue of $265 million to $280 million​.Qtrly ‍ cash, cash equivalents & marketable securities were $316.9 million at Sept. 30, 2017, versus $297.5 million at June 30, 2017​.  Full Article

Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Halozyme Therapeutics Inc :Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex with co's enhanze technology​.Halozyme Therapeutics Inc - will receive a $15 million milestone payment from Janssen following dosing of third patient in a phase 3 trial​.  Full Article

Halozyme licenses new Enhanze target for $30 mln upfront payment
Thursday, 14 Sep 2017 

Sept 14 (Reuters) - Halozyme Therapeutics Inc ::Halozyme licenses new enhanze target for $30 million upfront payment, future milestones and royalties.Halozyme therapeutics-co will receive initial $30 million with potential to earn additional payments of up to $160 million, subject to certain milestones​.Halozyme therapeutics-licensed its enhanze drug-delivery technology to roche for exclusive development of an undisclosed therapeutic target.  Full Article

Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology
Thursday, 14 Sep 2017 

Sept 14 (Reuters) - Bristol-Myers Squibb Co :Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology.Bristol-Myers Squibb Co - ‍Halozyme to receive $105 million upfront payment, plus future milestones and royalties​.Bristol-Myers Squibb Co - ‍Halozyme to receive $105 million upfront payment, plus future milestones and royalties​.Bristol-Myers Squibb Co - ‍provides Bristol-Myers Squibb access to enhanze technology for up to 11 targets​.Bristol-Myers Squibb Co - ‍collaboration may extend to a maximum of 11 targets​.Bristol-Myers Squibb Co - ‍for Bristol-Myers Squibb, transaction is expected to be dilutive to non-gaap earnings per share in 2017​.Bristol-Myers - ‍Halozyme has potential to earn milestone payments of upto $160 million for each nominated collaboration targets,additional milestone payments​.Bristol-Myers Squibb says ‍for co, deal is expected to be dilutive to non-GAAP earnings per share in 2017 and 2018 by approximately $0.01​.Bristol-Myers Squibb Co - ‍for co, deal is expected to be dilutive to non-GAAP earnings per share by about $0.05 in 2019​.  Full Article

Halozyme reports Q2 loss per share $0.23
Tuesday, 8 Aug 2017 

Aug 9 (Reuters) - Halozyme Therapeutics Inc -:Halozyme reports second quarter 2017 results.Q2 loss per share $0.23.Q2 revenue $33.8 million versus I/B/E/S view $31.8 million.Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $115 million to $130 million.Halozyme Therapeutics Inc sees 2017 net revenue of $115 million to $130 million.Halozyme Therapeutics Inc sees 2017 operating cash burn of $75 million to $85 million.Halozyme Therapeutics Inc sees 2017 year-end cash balance of $245 million to $260 million.FY2017 revenue view $132.1 million -- Thomson Reuters I/B/E/S.  Full Article

Halozyme announces initiation of clinical trial collaboration
Thursday, 13 Jul 2017 

July 13 (Reuters) - Halozyme Therapeutics Inc ::Initiation of clinical trial collaboration evaluating Halozyme's pegph20 in combination with anti-PDL1 immunotherapy.Halozyme Therapeutics says combination will be tested in patients with previously treated metastatic pancreatic ductal adenocarcinoma.Says ‍study is sponsored by and funded by Genentech​.  Full Article

Halozyme Therapeutics, unit entered into first amendment to amended, restated lease with BMR-11388 Sorrento Valley Road
Wednesday, 5 Jul 2017 

July 5 (Reuters) - Halozyme Therapeutics Inc ::Halozyme Therapeutics Inc - co, unit entered into a first amendment to amended and restated lease with bmr-11388 sorrento valley road lp.Halozyme Therapeutics Inc - co, unit also entered into a first amendment to lease with bmr-sorrento plaza llc - sec filing.Halozyme Therapeutics Inc - lease amendments effectively extend company's tenancy at these facilities for an additional five years.Halozyme Therapeutics Inc - 11388 lease amendment extension commences on January 15, 2018 and expires on january 14, 2023.  Full Article

Halozyme Therapeutics prices public offering of common stock
Friday, 19 May 2017 

May 18 (Reuters) - Halozyme Therapeutics Inc :Halozyme Therapeutics prices public offering of common stock.Priced previously announced underwritten public offering of 10 million shares of its common stock at $12.50 per share.  Full Article

BRIEF-Abzena Gets Notice From Halozyme Of Termination Of Agreement

* GOT NOTICE FROM HALOZYME THERAPEUTICS OF TERMINATION OF COLLABORATION, LICENCE AGREEMENT RELATING TO HALOZYME'S USE OF CO'S THIOBRIDGE LINKER TECH Source text for Eikon: Further company coverage: